- Previous Close
0.0049 - Open
0.0049 - Bid --
- Ask --
- Day's Range
0.0049 - 0.0164 - 52 Week Range
0.0009 - 0.1076 - Volume
25,200 - Avg. Volume
2,655 - Market Cap (intraday)
16.162M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Sep 25, 2024 - Sep 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.
auscann.com.au--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: ACNNF
View MorePerformance Overview: ACNNF
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACNNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACNNF
View MoreValuation Measures
Market Cap
5.29M
Enterprise Value
4.87M
Trailing P/E
20.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.12
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1.67%
Return on Equity (ttm)
-78.72%
Revenue (ttm)
1.36M
Net Income Avi to Common (ttm)
-9.44M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.02M